Trial Profile
Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension [EXTENSION OF 700060028]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2014
Price :
$35
*
At a glance
- Drugs Patritumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 25 Aug 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 04 Jul 2013 New trial record